New Drug Candidate ERAS 0015 Overcomes Historical Barriers in Targeting RAS Gene Mutations
AURORAS-1 investigators reported tumors shrank in 11 of 25 previously treated pancreatic cancer patients at 32 milligrams; larger trials must confirm safety.
- On Friday, Erasca presented early-stage trial results for ERAS-0015, an experimental pill that shrank tumors in patients with advanced lung and pancreatic cancer at the 38th EORTC-NCI-AACR Symposium in Barcelona.
- ERAS-0015 acts as a 'molecular glue' that blocks faulty RAS proteins, effectively shutting down vital signals cancer cells need to grow and multiply. This targets tumors driven by RAS mutations, previously thought impossible to drug.
- Tumors shrank in 44% of 25 previously treated pancreatic cancer patients receiving 32 mg, while 60% of five lung cancer patients who had received prior immunotherapy also responded to the treatment.
- Medical Oncologist Dr. Judy Wang, Florida Cancer Specialists and Research Institute, stated the findings demonstrate 'clinically meaningful activity' for patients with few options. Twelve patients reported severe treatment-related side effects.
- Erasca plans to start late-stage clinical trials in 2027 to confirm safety and efficacy in pancreatic and lung cancers, also testing ERAS-0015 alongside the experimental treatment ERAS-4001.
11 Articles
11 Articles
Erasca’s pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial - Regional Media News
Nov 20 (Reuters) - Erasca said on Friday its experimental cancer pill shrank tumors in many patients with advanced pancreatic and lung cancers in an early-stage trial. • Of 25 patients with pancreatic cancer taking a 32 mg daily dose of the drug, ERAS-0015, 44% [...]
'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers
Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.
The results of the phase I AURORAS-1 clinical trial of a cancer drug called ERAS-0015, have shown that it is safe and has managed to reduce the size of lung and pancreas tumors. Obtained in 148 patients "are important because ERAS-0015 acts on tumors whose growth is driven by mutations of the RAS gene (a family of genes that regulates cell growth and division). Until recently it was considered impossible to design drugs capable of acting effecti…
Erasca’s pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial
Nov 20 (Reuters) - Erasca said on Friday its experimental cancer pill shrank tumors in many patients with advanced pancreatic and lung cancers in an early-stage trial. • Of 25 patients with pancreatic cancer taking a 32 mg daily dose of the drug, ERA...
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium







